Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

CRC selects water-soluble paclitaxel for phase I trial

July 2, 1999

CDK4-specific antisense oligodeoxynucleotides for inhibition of tumors

July 1, 1999

Coulter, SmithKline Beecham file BLA for Bexxar

July 1, 1999

5-Halo- or nitrate-substituted paclitaxels under study at Bristol-Myers Squibb

July 1, 1999

Alza's Doxil approved in U.S. for treatment of refractory ovarian cancer

July 1, 1999

Valentis moves IL-2 gene therapy to phase II

July 1, 1999

InKine files two patent applications relating to thrombospondin receptor

July 1, 1999

NCI initiates phase I trials with patient-specific cancer vaccines

July 1, 1999

Introgen Therapeutics receives milestone payment from RPR

July 1, 1999

Aronex reports responses in phase II trial of Atragen as treatment of NHL

June 30, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...